Project Grant R03HL183265
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $118K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90095, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.564 million on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of long noncoding RNAs and micropeptides in inflammation, lipid metabolism, and atherosclerosis. The project spans two research aims. Aim 1 examines a macrophage micropeptide named BRIK, testing its role in integrating metabolic and immune signaling and its contribution to...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $1.368 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanosensitive signaling mechanisms that support endothelial cell resilience in the context of cardiovascular disease treatment. The research elucidates a mechanosensitive signaling domain in endothelial cells and tests how TRPV4-mediated calcium signaling promotes vascular resilience....
- The National Institutes of Health National Heart, Lung and Blood Institute awarded Boston Children's Hospital $1,628,604 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct molecular research on atherosclerosis regulation, with performance through June 30, 2028. The project investigates endothelial dysfunction and chronic inflammation as critical regulators of plaque destabilization in atherosclerosis, focusing on the role of CD47 as a cell-surface...
- The National Heart, Lung, and Blood Institute awarded Wake Forest University Health Sciences $2.402 million on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to map the molecular and cellular conversion of normal human coronary artery tissue to atherosclerotic plaque and identify therapeutic targeting opportunities for atherosclerotic vascular disease. The recipient will leverage its existing tissue biorepository of human coronary and aortic samples from trauma...
- The National Heart, Lung, and Blood Institute of the Department of Health and Human Services awarded the University of California, Los Angeles $3,134,805 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on alternative polyadenylation in cardiovascular disease. The recipient will integrate computational techniques with molecular, cellular, and animal model studies to elucidate how alternative polyadenylation (APA) contributes to cardiovascular...
- The National Heart, Lung, and Blood Institute awarded Yale University $126,177 on June 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund postdoctoral and early-career research investigating the role of intraflagellar transport protein IFT88 in smooth muscle cell phenotype and vascular remodeling. The research addresses mechanisms by which smooth muscle cells in blood vessel walls transition between differentiated and dedifferentiated phenotypes—a process...
- The National Heart, Lung, and Blood Institute awarded Yale University $838,491 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify novel gene variants that drive endothelial cell activation during atherosclerotic cardiovascular disease. The recipient will elucidate mechanisms by which gain-of-function defects in ZFYVE21, an endosome-associated protein highly expressed in endothelial cells, contribute to endothelial cell activation and exacerbate...
- The National Heart, Lung, and Blood Institute awarded the Scripps Research Institute $1,101,338 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer noncovalent antibody-enzyme thrombolytic complexes that function orthogonally to the natural hemostatic system. The project, R01HL184492, addresses limitations of current plasminogen activator therapies—including narrow therapeutic window, contraindications, and risks of neurotoxicity, bleeding, and...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $1,151,500 on March 9, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate macrophage biology in atherosclerosis and atherosclerosis-related cardiometabolic disease. The award funds a comprehensive program exploring the role of macrophage efferocytosis and resolution cycles in promoting fibrous cap thickening in atherosclerotic plaques and...
- The National Heart Lung and Blood Institute awarded the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center $852,991 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a longitudinal study of coronary inflammation detection using computed tomography. The recipient will measure epicardial fat density and peri-coronary fat attenuation in 17,138 non-contrast cardiac CT scans drawn from the Multi-Ethnic Study of Atherosclerosis...